A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

by 21% and Tresiba (insulin degludec) an ultra long-acting insulin, by 28%. The prices that patients will pay depends on their insurance scheme, with most paying a fixed co-payment for their ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

A new study has found that the diabetes drug tirzepatide helps people lower their blood sugar and lose weight more quickly than other commonly used treatments. Researchers at the East and North ...

The results of the ONWARDS 2 trial of insulin icodec showed that it was as effective as daily dosing with Novo Nordisk's Tresiba (insulin degludec) once per day at controlling blood glucose, as ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers ...

123 adults with type 1 diabetes were randomly assigned to technosphere insulin plus insulin degludec (Tresiba, Novo Nordisk) with use of a Dexcom G7 continuous glucose monitor, or usual care with ...